AngioDynamics (NASDAQ:ANGO) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a research report report published on Sunday morning.

ANGO has been the subject of a number of other reports. Canaccord Genuity Group upped their target price on AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Stock Performance

ANGO stock opened at $13.16 on Friday. AngioDynamics has a 52 week low of $8.27 and a 52 week high of $13.99. The company has a market capitalization of $542.19 million, a PE ratio of -16.87 and a beta of 0.49. The company’s 50-day simple moving average is $12.50 and its 200 day simple moving average is $10.85.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm had revenue of $75.71 million during the quarter, compared to the consensus estimate of $72.69 million. During the same quarter in the previous year, the firm posted ($0.11) EPS. The business’s revenue for the quarter was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, analysts forecast that AngioDynamics will post -0.37 EPS for the current year.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer bought 10,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were purchased at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. The trade was a 1.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction on Tuesday, October 21st. The shares were acquired at an average cost of $11.81 per share, with a total value of $118,100.00. Following the purchase, the senior vice president owned 93,597 shares of the company’s stock, valued at approximately $1,105,380.57. This represents a 11.96% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 20,890 shares of company stock worth $239,532 over the last ninety days. 6.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AngioDynamics

Several hedge funds have recently added to or reduced their stakes in ANGO. Pier Capital LLC grew its stake in AngioDynamics by 40.5% in the second quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier’s stock valued at $6,887,000 after acquiring an additional 200,244 shares during the period. Divisadero Street Capital Management LP grew its position in AngioDynamics by 253.7% in the 2nd quarter. Divisadero Street Capital Management LP now owns 3,395,430 shares of the medical instruments supplier’s stock valued at $33,683,000 after purchasing an additional 2,435,365 shares during the period. Stonepine Capital Management LLC acquired a new stake in AngioDynamics in the 2nd quarter valued at $765,000. Cubist Systematic Strategies LLC increased its stake in AngioDynamics by 71.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 232,473 shares of the medical instruments supplier’s stock valued at $2,183,000 after purchasing an additional 97,123 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in AngioDynamics during the first quarter worth $939,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.